| Page | ||||
|---|---|---|---|---|
| Trustees and Officers | . | 2-3 | ||
| Chairman's Statement |
4-5 | |||
| Trustees' Report | 6-9 | |||
| Statement ofTrustees' | responsibilities | |||
| Report ofthe Independent | Auditor | 10-11 | ||
| Grants awarded | 12 | |||
| Statement ofFinancial | Activities | . .... | 13 | |
| Balance sheet | 14 | |||
| Cash Flow Statement | . | 15 | ||
| Notes to the Financial | Statements | 16-21 |
| Terry Madden | Chairman | ||
|---|---|---|---|
| Roger Allsopp | |||
| Tony Cottam | |||
| Professor Jonathan Cole | |||
| Professor Max Crispin | |||
| Professor Diana Eccles | Dean ofthe Faculty ofMedicine, | University | of Southampton. |
| Stella Gardener | Retired 23.04.21 | ||
| Professor SirCharles George | |||
| Luke March | Appointed 23.04.21 | ||
| Nick Page | |||
| Angela Suggate FCCA | |||
| Michael Wilkins |
| Independent | Auditors | Sheen Stickland |
|---|---|---|
| Chartered Accountants |
||
| Statutory Auditors | ||
| 7East Pallant | ||
| Chiche ster | ||
| West Sussex | ||
| PO191TR | ||
| Honorary | Solicitors | Womble Bond Dickinson (UK) LLP |
| Oceana House | ||
| Commercial Road | ||
| Southampton | ||
| SO151GA |
| Faculty of | Medicine, University | ofSouthampton. |
|---|---|---|
| Faculty of | Medidne, University |
ofSouthampton |
| Faculty of | Medicine, University | ofSouthampton |
| Faculty of | Environmental and Life Sciences |
|
| University | ofSouthampton | |
| Faculty of | Environmental and Life Sciences |
|
| University | ofSouthampton | |
| Faculty of | Physical Sciences and Engineering | |
| University | ofSouthampton | |
| Faculty of | Medicine, University | ofSouthampton |
| Faculty of | Physical Sciences and Engineering, | |
| University | ofSouthampton | |
| Faculty of | Medicine, University | ofSouthampton |
| Faculty of | Medicine, University | ofSouthampton |
| Faculty of | Medicine, University | ofSouthampton |
| Faculty of | Environmental and Life Sciences, |
|
| University | ofSouthampton | |
| Faculty of | Environmental and Life Sciences, |
|
| University | ofSouthampton |
| Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| value | |||||||||
| R | |||||||||
| AB01 | DrZoe Walters | 49,986 | |||||||
| Faculty ofMedicine | |||||||||
| PhD Studensthipjointly funded with Rosetrees |
Trust | ||||||||
| Student-Jack Hamngton |
|||||||||
| Investigating the therapeutic |
efficacy ofEZH2inhibitors | forthe treatment of | |||||||
| diseases with pathogenic |
histone modifying enzyme mutations. |
||||||||
| AB02 | 3"Year Medical Student Project Presentation | Grants | 1,000 | ||||||
| AB03 | Dr Franklin de Nobrega | 20,000 | |||||||
| Faculty ofthe Environment | and Life Sciences | ||||||||
| Vsing phages togive new life tooldantibiotics | against superbugs | ||||||||
| AB04 | Dr Adnan Khan |
19,933 | |||||||
| Faculty ofMedicine | |||||||||
| A clinical study evaluatihg | biomarkers ofimmunosenescencein |
the | |||||||
| progression ofAge Related | Macular DegeneratIon | (The Immuno | AMO Study) | ||||||
| AB05 | Dr Nicole Prior | 20,000 | |||||||
| Faculty ofthe Environment | and Life Sciences | ||||||||
| Chemically defined biomimetic hydrogels tosupport pancreas organoids forthe development ofclinical |
human therapies |
ilver | and | ||||||
| Annual Total 2021 |
110,919 | ||||||||
| Annual Tota/2020 |
91,22B |
| Balance Sheet asat 31 | December 2021 | |||
|---|---|---|---|---|
| Note | 2021 | 2020 | ||
| Fixed Assets | ||||
| Tangible Assets | 10 | |||
| Inmstments | 11 | 1,339,252 | 868,776 | |
| 1,339,252 | 868,776 | |||
| Current Assets | ||||
| lffMstmen'ts | 12 | 31,503 | 32,624 | |
| Debtors | 13 | 50,512 | 50,604 | |
| Cash at bank and in hand | 670,924 | 129,175 | ||
| 752,939 | 212,403 | |||
| Current Uabilities | ||||
| Amounts falling due within |
one year | 14 | (256,993) | (394,771) |
| Net Current Assets I(Liabilities) | 495,946 | (182,368) | ||
| Total Assets less Cunsnt Uabilities | 1,835,198 | 686,408 | ||
| Liabilities | ||||
| Amounts falling due after |
more than one year | 15 | (171,019) | (146,715) |
| 16 | 1,664,179 | 539,693 | ||
| Funds | ||||
| Unrestricted | General | 18 | 541,698 | 477,295 |
| Restricted | 17 | 1,122,481 | 62,398 | |
| Total Funds | 1,664,179 | 539,693 |
| Statement ofFinancial | Acdvities | Acdvities | ||||||
|---|---|---|---|---|---|---|---|---|
| Forthe Year Ended 31stDecember 2021 | ||||||||
| Note | Unrestricted | Restricted | Total | Total | ||||
| Funds | Funds | 2021 | 2020 | |||||
| E | E | E | E | |||||
| Income and endowments | from | |||||||
| Donations | 2a | 9,035 | 10,000 | 19,035 | 42,319 | |||
| Legacies | 2b | 16,366 | 1,050,000 | 1,066,366 | 151,000 | |||
| Other trading actlNties |
2,641 | 2,641 | 3,560 | |||||
| Investment income |
50,903 | 50,903 | 45,979 | |||||
| Total | 76,304 | 1,062,641 | 1,138,945 | 242,858 | ||||
| Expenditure on |
||||||||
| Raising Funds | 4 | 15,302 | - | 15,302 | 17,114 | |||
| Charitable actiuties |
5,6 | 120,953 | (2,442) | 116,511 | 94,286 | |||
| Total | 136,255 | (2,442) | 133,813 | 111,400 | ||||
| Other recognised gains/(losses) |
||||||||
| Gains/(losses) on irnestment |
assets | 119,354 | 119,354 | (193,733) | ||||
| Net income/(expenditure) | 59,403 | 1,065,083 | 1,124,486 | (62,275) | ||||
| Transfers between funds |
17 | 5,000 | (5,000) | |||||
| Net movement in funds |
64,403 | 1,060,083 | 1,124,486 | (62,2?5) | ||||
| Reconciliation cftunds | ||||||||
| Balances brought Onward |
at | 1"January | 2021 | 477,295 | 62,398 | 539,693 | 601,968 | |
| Balances carried Ibrward | at | 31"December 2021 | 541,698 | 1,122,481 | 1,664,179 | 539,693 |
| Cash Flow Statement | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | |||||||
| Cash f'rom Operating Aclvities |
Note 1 | 840,846 | (20,135) | |||||
| Cash low from Investing | ||||||||
| Purchase ofFixed Asset Investments | (500,000) | |||||||
| Sale ofFixed Asset Inv | stments | 150,000 | 50,000 | |||||
| Sale ofCunent Asset Investments | 17,500 | |||||||
| Distributions Receimd |
50,903 | 45,979 | ||||||
| (299,097) | 113,479 | |||||||
| Change in cash and cash |
equivalents | in the | period | 541,749 | 93,344 | |||
| Cash and cash equivalents | at 1stJanuary | 2021 | 129,175 | 35,831 | ||||
| Cash and cash eqnivalenm | at 31st | Oecemher | 2821 | 670,924 | 129,175 |
| Cash from operating Ac |
tivities | |||
|---|---|---|---|---|
| Net income/(expenditure) | for reporting | period per SOFA | 1,124,486 | (62,275) |
| Adjustments Ibr: |
||||
| Distributions received |
(50,903) | (45,979) | ||
| Decrease in Debtors | 92 | 8,132 | ||
| Increase / (Decrease) |
in Creditors | 1,482 | (19,005) | |
| (Decrease) in Grants | payable | (114,957) | (94,741) | |
| (Gain)/Loss on investments |
(119,354) | 193,733 | ||
| 840,846 | (20,135) |
| 2a. Donations | 2021 | 2020 |
|---|---|---|
| Trusts and foundations | 12,000 | 30,950 |
| Individuals | 6,366 | 6,313 |
| Gift aid | 647 | 21 |
| Corporate | 22 | 35 |
| Other | 5,000 | |
| 19,035 | 42,319 | |
| 2b. Legacies | ||
| Legacies | 1,066,366 | 151,000 |
| 2021 | 2020 | ||
|---|---|---|---|
| Income from UK quoted in~tments | 50,903 | 45,979 | |
| 50,903 | 45,979 | ||
| 4. | Raising Funds |
| Unrestricted | Restricted | 2021 | 2020 | ||
|---|---|---|---|---|---|
| Eat Costs | 1,750 | ||||
| Brochures | and Leallets | 3,126 | 3,126 | 2,990 | |
| Admrtising | 260 | 260 | 690 | ||
| Support Costs | 11,916 | 11,916 | 11,684 | ||
| 15,302 | 15,302 | 17,114 |
| Grant | ||
|---|---|---|
| Funding of | Support | |
| Activities | Costs | Total |
| E | ||
| 96,929 | 21,583 | 118,511 |
| 96,929 | 21,583 | 118,511 |
| 6. Allocatio |
n ofSupport Costa | |||
|---|---|---|---|---|
| Raising | Charitable | Total | ||
| Funda | Activities | |||
| K | E | |||
| Oflice Costs | 1,421 | 1,528 | 2,949 | |
| Professional | Fees | 10,495 | 16,154 | 26,649 |
| Audit Fees | 3,900 | 3,900 | ||
| 11,918 | 21,582 | 33,498 |
| 9. Auditors and In | dependent | Examiners remunera6on | ||
|---|---|---|---|---|
| 2021 | ||||
| K | ||||
| Auditors/independent | Examiners | Senices | 3,900 | 2,400 |
| 3.900 | 2.400 |
| 10. Tangible | Fixed | Assets | ||||
|---|---|---|---|---|---|---|
| Fixtures, Fittings | ||||||
| and | Equipment | |||||
| F. | ||||||
| Cost at 1» January | 2021 | 190 | ||||
| Additions | ||||||
| Disposals | ||||||
| Cost at 31~ December 2021 | 190 | |||||
| Accumulated | depreciation | at 1" January | 2021 | 190 | ||
| Charge ibr year | ||||||
| Disposals | ||||||
| Accumulated | depreciation | at 31" December 2021 | 190 | |||
| Net BookValue | ||||||
| 31" December | 2021 | |||||
| 31" December | 2020 | |||||
| 11.Investments atmarket value: fixed assets |
||||||
| Equities - UK | ||||||
| Market Value | at 1st | January | 2021 | 868,776 | ||
| Additions | 500,000 | |||||
| Disposals | (131,939) | |||||
| Unrealised Gain Ibr the year |
102,415 | |||||
| Market value | at 31stDecember 2021 | 1,339,252 |
| Go~ant | Stocks | ||
|---|---|---|---|
| Market Value at 1stJanuary | 2021 | 32,624 | |
| Additions | |||
| Disposals | |||
| Unrealised | Loss for the year | (1,121) | |
| Market value at 31stDecember 2021 | 31,503 |
| 13. Debtors | |||
|---|---|---|---|
| 2021 | 2020 | ||
| E | |||
| Other debtors | 50,095 | 50,187 | |
| Prepayments | 417 | 417 | |
| 50,512 | 50,604 | ||
| 14Creditors: amounts | falling due within one year | ||
| 2021 | 2020 | ||
| Grants payable | 248,976 | 388,236 | |
| Accruals | 8,017 | 6,535 | |
| 256,993 | 394,771 |
| 15.Cr | editors: amounts falling due afiar |
more than one year | |
|---|---|---|---|
| 2021 | 2020 | ||
| Grants | payable | 171,019 | 146,715 |
| 171,019 | 146,715 |
| Unrestricted | Restricted | Total | |||||
|---|---|---|---|---|---|---|---|
| Funds | Funds | Funds | |||||
| R | |||||||
| Fixed | Assets | 848,632 | 490,620 | 1,339,252 | |||
| Current | Assets | 82,015 | 670,924 | 752,939 | |||
| Current | Liabilities | (244,493) | (12,500) | (256,993) | |||
| Amounts | falling | due | alter more | ||||
| than | 1 year | (144,457) | (26,562) | (171,019) | |||
| Total | Net Assets | 536,697 | 1 127462 | 1,664,179 |
| 17. Restricted | 17. Restricted | Funds | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2020 | ||||||
| K | f | ||||||
| Opening | balance at | 1» January | 2021 | 62,398 | 95,539 | ||
| Net moment | in restricted | funds | 1,065,083 | (33,141) | |||
| Transfer | to unrestricted | general funds |
(5,000) | ||||
| Balance | at 31 | December | 2021 | 1,122,481 | 62,398 |
| specIc purpose by the Trustees |
at a future date. | ||||
|---|---|---|---|---|---|
| Opening | Incoming | Resources | Transfers | Closing | |
| balance | Resources | Expended | between | balance at | |
| at 1st | funds | 3162 | |||
| January | December | ||||
| 2021 | 2021 | ||||
| Allergies | 9,506 | 9,506 | |||
| Brain Injury | 9,089 | 9,089 | |||
| Cancer | 17,477 | 1,062,641 | 1,080,118 | ||
| Cancer [Cenical] | 2,442 | 2,442 | |||
| Diabetes | 135 | 135 | |||
| Meningitis | 7,247 | 7,247 | |||
| Staa Mills lund | 11,882 | 11,882 | |||
| States ofGuernsey | 5,000 | (5,000) | |||
| Other disease specilic funds Tolal |
2,062 62,388 |
1,062,641 | 2,442 | ~5,000) | 2,062 1,122,481 |
| 2021 | 2020 | |||||
|---|---|---|---|---|---|---|
| f | K | |||||
| Opening | balance at 1 | January | 2021 | 477,295 | 506,429 | |
| Net moment | in Free t0nds | 59,403 | (29,134) | |||
| Transfsr | from | Restricted | Funds | 5,000 | ||
| Balance | at 31"December 2021 | 541,698 | 4?7,295 |